Skip to main
ANIK

Anika Therapeutics (ANIK) Stock Forecast & Price Target

Anika Therapeutics (ANIK) Analyst Ratings

Based on 1 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Anika Therapeutics Inc. reported a 21% growth in its international osteoarthritis (OA) pain revenue compared to the same quarter last year, driven by favorable order timing, and anticipates a positive cash position projected to reach around $60 million within the next 12 months. The company's regenerative solutions business also demonstrated robust performance with a 25% growth in the latest quarter, propelled by new product developments for the Integrity patch, which are expected to enhance its market presence and fuel continued growth. Additionally, Anika's fourth-quarter financial results surpassed expectations, showcasing a free cash flow of $5.0 million and indicating a strong trajectory towards significantly increased procedures and revenue in the upcoming years.

Bears say

Anika Therapeutics Inc reported a revenue decline of 5.9% year-over-year, generating $27.8 million, which fell short of revenue expectations despite outperforming adjusted EPS and cash generation metrics. The company's gross margin was disappointing at 56%, lower than the 58% estimate, partly due to ongoing production yield issues and persistent price headwinds within the U.S. market, which negatively impact profitability. Additionally, management's financial guidance indicates a contrasting outlook with anticipated 12-18% revenue growth in the commercial channel but a significant projected decline of 16-20% in the OEM channel, compounding the negative outlook given the failure of its pivotal FastTrack trial for Hyalofast, which did not meet its primary endpoints.

Anika Therapeutics (ANIK) has been analyzed by 1 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anika Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anika Therapeutics (ANIK) Forecast

Analysts have given Anika Therapeutics (ANIK) a Buy based on their latest research and market trends.

According to 1 analysts, Anika Therapeutics (ANIK) has a Buy consensus rating as of Mar 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anika Therapeutics (ANIK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.